Cargando…

Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials

The liver centralizes the systemic metabolism and thus controls and modulates the functions of the central and peripheral nervous systems, the immune system, and the endocrine system. In addition, the liver intervenes between the splanchnic and systemic venous circulation, determining an abdominal p...

Descripción completa

Detalles Bibliográficos
Autores principales: de Miguel, Maria P., Prieto, I., Moratilla, A., Arias, J., Aller, M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525815/
https://www.ncbi.nlm.nih.gov/pubmed/31191671
http://dx.doi.org/10.1155/2019/3945672
_version_ 1783419770441302016
author de Miguel, Maria P.
Prieto, I.
Moratilla, A.
Arias, J.
Aller, M. A.
author_facet de Miguel, Maria P.
Prieto, I.
Moratilla, A.
Arias, J.
Aller, M. A.
author_sort de Miguel, Maria P.
collection PubMed
description The liver centralizes the systemic metabolism and thus controls and modulates the functions of the central and peripheral nervous systems, the immune system, and the endocrine system. In addition, the liver intervenes between the splanchnic and systemic venous circulation, determining an abdominal portal circulatory system. The liver displays a powerful regenerative potential that rebuilds the parenchyma after an injury. This regenerative mission is mainly carried out by resident liver cells. However, in many cases this regenerative capacity is insufficient and organ failure occurs. In normal livers, if the size of the liver is at least 30% of the original volume, hepatectomy can be performed safely. In cirrhotic livers, the threshold is 50% based on current practice and available data. Typically, portal vein embolization of the part of the liver that is going to be resected is employed to allow liver regeneration in two-stage liver resection after portal vein occlusion (PVO). However, hepatic resection often cannot be performed due to advanced disease progression or because it is not indicated in patients with cirrhosis. In such cases, liver transplantation is the only treatment possibility, and the need for transplantation is the common outcome of progressive liver disease. It is the only effective treatment and has high survival rates of 83% after the first year. However, donated organs are becoming less available, and mortality and the waiting lists have increased, leading to the initiation of living donor liver transplantations. This type of transplant has overall complications of 38%. In order to improve the treatment of hepatic injury, much research has been devoted to stem cells, in particular mesenchymal stem cells (MSCs), to promote liver regeneration. In this review, we will focus on the advances made using MSCs in animal models, human patients, ongoing clinical trials, and new strategies using 3D organoids.
format Online
Article
Text
id pubmed-6525815
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65258152019-06-12 Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials de Miguel, Maria P. Prieto, I. Moratilla, A. Arias, J. Aller, M. A. Stem Cells Int Review Article The liver centralizes the systemic metabolism and thus controls and modulates the functions of the central and peripheral nervous systems, the immune system, and the endocrine system. In addition, the liver intervenes between the splanchnic and systemic venous circulation, determining an abdominal portal circulatory system. The liver displays a powerful regenerative potential that rebuilds the parenchyma after an injury. This regenerative mission is mainly carried out by resident liver cells. However, in many cases this regenerative capacity is insufficient and organ failure occurs. In normal livers, if the size of the liver is at least 30% of the original volume, hepatectomy can be performed safely. In cirrhotic livers, the threshold is 50% based on current practice and available data. Typically, portal vein embolization of the part of the liver that is going to be resected is employed to allow liver regeneration in two-stage liver resection after portal vein occlusion (PVO). However, hepatic resection often cannot be performed due to advanced disease progression or because it is not indicated in patients with cirrhosis. In such cases, liver transplantation is the only treatment possibility, and the need for transplantation is the common outcome of progressive liver disease. It is the only effective treatment and has high survival rates of 83% after the first year. However, donated organs are becoming less available, and mortality and the waiting lists have increased, leading to the initiation of living donor liver transplantations. This type of transplant has overall complications of 38%. In order to improve the treatment of hepatic injury, much research has been devoted to stem cells, in particular mesenchymal stem cells (MSCs), to promote liver regeneration. In this review, we will focus on the advances made using MSCs in animal models, human patients, ongoing clinical trials, and new strategies using 3D organoids. Hindawi 2019-05-02 /pmc/articles/PMC6525815/ /pubmed/31191671 http://dx.doi.org/10.1155/2019/3945672 Text en Copyright © 2019 Maria P. de Miguel et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
de Miguel, Maria P.
Prieto, I.
Moratilla, A.
Arias, J.
Aller, M. A.
Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials
title Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials
title_full Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials
title_fullStr Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials
title_full_unstemmed Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials
title_short Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials
title_sort mesenchymal stem cells for liver regeneration in liver failure: from experimental models to clinical trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525815/
https://www.ncbi.nlm.nih.gov/pubmed/31191671
http://dx.doi.org/10.1155/2019/3945672
work_keys_str_mv AT demiguelmariap mesenchymalstemcellsforliverregenerationinliverfailurefromexperimentalmodelstoclinicaltrials
AT prietoi mesenchymalstemcellsforliverregenerationinliverfailurefromexperimentalmodelstoclinicaltrials
AT moratillaa mesenchymalstemcellsforliverregenerationinliverfailurefromexperimentalmodelstoclinicaltrials
AT ariasj mesenchymalstemcellsforliverregenerationinliverfailurefromexperimentalmodelstoclinicaltrials
AT allerma mesenchymalstemcellsforliverregenerationinliverfailurefromexperimentalmodelstoclinicaltrials